Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adamis Pharmaceuticals has received the US Food and Drug Administration's (FDA) acceptance for investigational new drug (IND) application for APC-100, indicated as a treatment for prostrate cancer (Pca).
Subscribe to our email newsletter
APC-100 is an orally available drug and has demonstrated multiple activities in various model systems.
Adamis Pharmaceuticals intends to commence APC-100 Phase 1/2a trials in patients who are suffering from castrate resistant prostate cancer (CRPR).
In the trials, the company will evaluate each patient for toxicity, biochemical responses (Prostate Specific Antigen), radiographic and clinical responses.
Adamis Pharma president and CEO Dennis Carlo said moving APC-100 into human clinical trials is another milestone for the company.